BRAF and neoplasm: Pre-clinical and clinical studies show that targeting BRAF using RAF-selective inhibitors results in remarkable tumour shrinkage in BRAFV600E mutant melanomas; however, many of the treated patients exhibit therapy resistance due to the highly heterogeneous tumour profile [3].